A nonrandomized open-label phase 2 trial of nonischemic heart preservation for human heart transplantation

A nonrandomized open-label phase 2 trial of nonischemic heart preservation for human heart transplantation

Ischemia and reperfusion damage contribute to early graft dysfunction and recipient’s death. Here the authors show the feasibility and safety of a non-ischemic heart preservation method for heart transplantation in a non-randomized trial.

Bibliographic Details
Main Authors: Johan Nilsson, Victoria Jernryd, Guangqi Qin, Audrius Paskevicius, Carsten Metzsch, Trygve Sjöberg, Stig Steen
Format: Article
Language:English
Published: Nature Publishing Group 2020-06-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-020-16782-9
id doaj-f39aecfe4ca9407ca1f37c429ffaeb07
record_format Article
spelling doaj-f39aecfe4ca9407ca1f37c429ffaeb072021-06-13T11:18:57ZengNature Publishing GroupNature Communications2041-17232020-06-011111810.1038/s41467-020-16782-9A nonrandomized open-label phase 2 trial of nonischemic heart preservation for human heart transplantationJohan Nilsson0Victoria Jernryd1Guangqi Qin2Audrius Paskevicius3Carsten Metzsch4Trygve Sjöberg5Stig Steen6Department of Clinical Sciences Lund, Cardiothoracic Surgery, Lund University and Skane University HospitalDepartment of Clinical Sciences Lund, Cardiothoracic Surgery, Lund University and Skane University HospitalDepartment of Clinical Sciences Lund, Cardiothoracic Surgery, Lund University and Skane University HospitalDepartment of Clinical Sciences Lund, Cardiothoracic Surgery, Lund University and Skane University HospitalDepartment of Clinical Sciences Lund, Cardiothoracic Surgery, Lund University and Skane University HospitalDepartment of Clinical Sciences Lund, Cardiothoracic Surgery, Lund University and Skane University HospitalDepartment of Clinical Sciences Lund, Cardiothoracic Surgery, Lund University and Skane University HospitalIschemia and reperfusion damage contribute to early graft dysfunction and recipient’s death. Here the authors show the feasibility and safety of a non-ischemic heart preservation method for heart transplantation in a non-randomized trial.https://doi.org/10.1038/s41467-020-16782-9
collection DOAJ
language English
format Article
sources DOAJ
author Johan Nilsson
Victoria Jernryd
Guangqi Qin
Audrius Paskevicius
Carsten Metzsch
Trygve Sjöberg
Stig Steen
spellingShingle Johan Nilsson
Victoria Jernryd
Guangqi Qin
Audrius Paskevicius
Carsten Metzsch
Trygve Sjöberg
Stig Steen
A nonrandomized open-label phase 2 trial of nonischemic heart preservation for human heart transplantation
Nature Communications
author_facet Johan Nilsson
Victoria Jernryd
Guangqi Qin
Audrius Paskevicius
Carsten Metzsch
Trygve Sjöberg
Stig Steen
author_sort Johan Nilsson
title A nonrandomized open-label phase 2 trial of nonischemic heart preservation for human heart transplantation
title_short A nonrandomized open-label phase 2 trial of nonischemic heart preservation for human heart transplantation
title_full A nonrandomized open-label phase 2 trial of nonischemic heart preservation for human heart transplantation
title_fullStr A nonrandomized open-label phase 2 trial of nonischemic heart preservation for human heart transplantation
title_full_unstemmed A nonrandomized open-label phase 2 trial of nonischemic heart preservation for human heart transplantation
title_sort nonrandomized open-label phase 2 trial of nonischemic heart preservation for human heart transplantation
publisher Nature Publishing Group
series Nature Communications
issn 2041-1723
publishDate 2020-06-01
description Ischemia and reperfusion damage contribute to early graft dysfunction and recipient’s death. Here the authors show the feasibility and safety of a non-ischemic heart preservation method for heart transplantation in a non-randomized trial.
url https://doi.org/10.1038/s41467-020-16782-9
work_keys_str_mv AT johannilsson anonrandomizedopenlabelphase2trialofnonischemicheartpreservationforhumanhearttransplantation
AT victoriajernryd anonrandomizedopenlabelphase2trialofnonischemicheartpreservationforhumanhearttransplantation
AT guangqiqin anonrandomizedopenlabelphase2trialofnonischemicheartpreservationforhumanhearttransplantation
AT audriuspaskevicius anonrandomizedopenlabelphase2trialofnonischemicheartpreservationforhumanhearttransplantation
AT carstenmetzsch anonrandomizedopenlabelphase2trialofnonischemicheartpreservationforhumanhearttransplantation
AT trygvesjoberg anonrandomizedopenlabelphase2trialofnonischemicheartpreservationforhumanhearttransplantation
AT stigsteen anonrandomizedopenlabelphase2trialofnonischemicheartpreservationforhumanhearttransplantation
AT johannilsson nonrandomizedopenlabelphase2trialofnonischemicheartpreservationforhumanhearttransplantation
AT victoriajernryd nonrandomizedopenlabelphase2trialofnonischemicheartpreservationforhumanhearttransplantation
AT guangqiqin nonrandomizedopenlabelphase2trialofnonischemicheartpreservationforhumanhearttransplantation
AT audriuspaskevicius nonrandomizedopenlabelphase2trialofnonischemicheartpreservationforhumanhearttransplantation
AT carstenmetzsch nonrandomizedopenlabelphase2trialofnonischemicheartpreservationforhumanhearttransplantation
AT trygvesjoberg nonrandomizedopenlabelphase2trialofnonischemicheartpreservationforhumanhearttransplantation
AT stigsteen nonrandomizedopenlabelphase2trialofnonischemicheartpreservationforhumanhearttransplantation
_version_ 1721379970525167616

Similar Items